Kaibo Ding
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study.
Journal: Technology in cancer research & treatment
Published: May 27, 2026
Clinicopathologic features and therapeutic outcomes in EGFR/ALK-aberrations NSCLC with histologic transformation.
Journal: Journal of translational medicine
Published: August 02, 2025
Beyond ALK fusion positivity: structural complexity as a prognostic indicator in first-line ALK-TKI therapy.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: June 26, 2025
Histologic transformation after targeted therapy resistance in driver gene-positive NSCLC: mechanisms and therapeutic challenges.
Journal: Therapeutic advances in medical oncology
Published: March 24, 2025
Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window.
Journal: Cancer biology & medicine
Published: February 10, 2025
Distinct clinical features and epidemiological trends of very early and middle-aged early onset colorectal cancer based on SEER 17 and GBD 2021 data over the past 15 years.
Journal: BMC cancer
Published: February 03, 2025
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation.
Journal: Journal of translational medicine
Published: May 31, 2024
Exploration of efficacy of the first-line treatment for advanced non-small cell lung cancer with primary MET-amplification: Retrospective evaluation of 36 cases.
Journal: International immunopharmacology
Published: May 25, 2024
Efficacy of immunotherapy in RET fusion-positive NSCLC: A meta-analysis.
Journal: Heliyon
Published: January 16, 2024
Last Updated: 09/26/2026